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ARTICLE
OTUD7A Regulates Neurodevelopmental Phenotypes
in the 15q13.3 Microdeletion Syndrome
Mohammed Uddin,1,2,3,12 Brianna K. Unda,4,12 Vickie Kwan,4 Nicholas T. Holzapfel,4 Sean H. White,4
Leon Chalil,4 Marc Woodbury-Smith,1,5 Karen S. Ho,6 Erin Harward,6 Nadeem Murtaza,4 Biren Dave,4
Giovanna Pellecchia,1,2 Lia D’Abate,1,2,7 Thomas Nalpathamkalam,1,2 Sylvia Lamoureux,1,2 John Wei,1,2
Marsha Speevak,8 James Stavropoulos,9 Kristin J. Hope,4 Brad W. Doble,4 Jacob Nielsen,11
E. Robert Wassman,6 Stephen W. Scherer,1,2,10,13,* and Karun K. Singh4,13,*
Copy-number variations (CNVs) are strong risk factors for neurodevelopmental and psychiatric disorders. The 15q13.3 microdeletion
syndrome region contains up to ten genes and is associated with numerous conditions, including autism spectrum disorder (ASD),
epilepsy, schizophrenia, and intellectual disability; however, the mechanisms underlying the pathogenesis of 15q13.3 microdeletion
syndrome remain unknown. We combined whole-genome sequencing, human brain gene expression (proteome and transcriptome),
and a mouse model with a syntenic heterozygous deletion (Df(h15q13)/þ mice) and determined that the microdeletion results in
abnormal development of cortical dendritic spines and dendrite outgrowth. Analysis of large-scale genomic, transcriptomic, and prote-
omic data identifiedOTUD7A as a critical gene for brain function. OTUD7Awas found to localize to dendritic and spine compartments in
cortical neurons, and its reduced levels in Df(h15q13)/þ cortical neurons contributed to the dendritic spine and dendrite outgrowth
deficits. Our results reveal OTUD7A as a major regulatory gene for 15q13.3 microdeletion syndrome phenotypes that contribute to
the disease mechanism through abnormal cortical neuron morphological development.Introduction
Neurodevelopmental disorders include various conditions
characterized by deficits or delays in typical developmental
milestones that appear in childhood. Genetic studies indi-
cate that copy-number variations (CNVs), comprising dele-
tions or duplications of genomic DNA that may directly or
indirectly affect the dosage of genes, can be significant risk
factors for these disorders. Certain genomic contexts are
hotspots for recombination- and replication-based mecha-
nisms that result in microdeletions or microduplications.
While 5%–20% of developmentally delayed individuals
carry a rare large pathogenic CNV,1 the pathobiology is
poorly understood. Furthermore, formost CNVs associated
with neurodevelopmental disorders, the underlying genes
that contribute to the clinical phenotypes remain un-
known. The 22q11.2 and 16p11.2 microdeletions are two
specific CNVs associated with schizophrenia (MIM:
181500) and autism spectrum disorder (ASD) (MIM:
209850), respectively, in which substantial progress has
been made into the understanding of disease pathophysi-
ology.2–9 In both, modeling microdeletions in animal
models has accelerated the pace at which the underlying
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underlying CNV-associated phenotypes.10–14 Importantly,
these studies have led to potential drug therapies that have
been tested in preclinical mouse models,5,7,15 highlighting
the power of this approach.
The 15q13.3 1.53 Mb microdeletion syndrome (MIM:
612001) locus (chr15:30,910,306–32,445,407 [hg19]) that
resides within breakpoints BP4-BP5 on human chromo-
some 15 is a recurrent CNV that results in a highly
heterogeneous set of phenotypes including intellectual
disability (50%–60%), autism spectrum disorder (10%–
20%), epilepsy (30%) (MIM: 607208), and schizophrenia
(10%–20%).16–23 Among the more than 200 individuals
bearing 15q13.3 BP4-BP5 deletions who have been
described in the clinical literature, 80% exhibited ascertain-
ment-independent phenotypic manifestations; this implies
that one or more genes in the CNV may contribute to dis-
ease manifestation, including the incomplete penetrance
and variable expressivity observed.24 Individuals are typi-
cally heterozygous for the 15q13.3 microdeletion, which
encompasses seven protein-coding genes, one microRNA,
and two putative pseudogenes (ARHGAP11BI [MIM:
616310], LOC100288637, FAN1 [MIM: 613534], MTMR10,
TRPM1 [MIM: 603576], LOC283710, microRNA-211, KLF13M5G 0A4, Canada; 2Program in Genetics and Genome Biology (GGB), The
Rashid University of Medicine and Health Sciences, Dubai, UAE; 4Stem Cell
epartment of Biochemistry and Biomedical Sciences, McMaster University,
ersity, UK; 6Lineagen Inc., Salt Lake City, UT 84109, USA; 7Department of
partment of Laboratory Medicine and Pathobiology, University of Toronto,
edicine, The Hospital for Sick Children, Toronto, ON M5G 0A4, Canada;
11Synaptic Transmission, In Vitro, Neuroscience Research DK, H. Lundbeck
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[MIM: 605328], OTUD7A [MIM: 612024], and CHRNA7
[MIM: 118511]). Recently, a heterozygous mouse model of
the 15q13.3 microdeletion was generated (Df(h15q13)/þ
mice) that contains a deletion of the syntenic murine chro-
mosome region (mouse chromosome 7qC) corresponding
to the human CNV. Phenotypic manifestations of this
heterozygous mouse model include schizophrenia- and
epilepsy-related endophenotypes, notably long-term spatial
memory deficits, increased sensitivity to stress, and reduc-
tions in auditory-evoked gamma power (similar to schizo-
phrenia patients).25 Many of these observed clinical pheno-
types were replicated in another independent 15q13.3
heterozygous microdeletion mouse model.26
In contrast to the heterozygous deletion, the homozy-
gous deletion is extremely rare and only eight case subjects
have been reported in the literature.24,27,28 All reported
case subjects that carry the homozygous deletion mani-
fested severe cognitive and physiological impairments
including severe DD/ID, hypotonia, seizures, and visual
impairment.24 A recent study analyzed behavioral abnor-
malities of Df(h15q13)/ homozygous knock out (KO)
mice29 in which both copies of the genes within the locus
are deleted.27 While the majority of human case subjects
are carriers of a heterozygous microdeletion, the homozy-
gous KO mice displayed more pronounced phenotypes in
seizure susceptibility, ASD behavior-related phenotypes,
and auditory sensory processing, demonstrating a gene-
dosage dependency. While the underlying neurophysio-
logical abnormalities remain unknown, recent studies
using resting-state fMRI have revealed that Df(h15q13)/þ
mice display altered neuronal firing rates in the prefrontal
cortex30 and abnormal brain hyperconnectivity pat-
terns;31 however, the underlying molecular and physiolog-
ical brain abnormalities contributing to the mouse
behavioral, imaging, and electrophysiological phenotypes
remain unknown.
The complexities inherent in the identification of the
critical driver gene(s) in a given CNV are significant and
require evidence from multiple sources. With regard to
the 15q13.3 microdeletion, CHRNA7 (encoding a cholin-
ergic receptor) has been proposed as a driver gene, in
part because some patients have overlapping deletions
that encompass CHRNA7.20 Furthermore, CHRNA7 ago-
nists may improve cognition in humans with schizo-
phrenia32 and abnormal fMRI-derived brain connectivity
in Df(h15q13)/þ mice.31 However, Chrna7 KO mice
display very mild defects in synaptic function and
learning33–36 and have no consistent behavioral or neuro-
physiological phenotypes compared to Df(h15q13)/þ
mice.37 Furthermore, among clinical case subjects, many
of the deletions encompassing CHRNA7 also overlap the
adjacent gene OTUD7A.20 One study reported 43 case sub-
jects from the literature that had deletions encompassing
both CHRNA7 and the first exon of OTUD7A.24 The Data-
base of Genomic Variants (DGV) includes population
control subjects that carry CHRNA7 deletions, bringing
into question the penetrance of haplo-insufficiency ofThe AmericaCHRNA7.38,39 Another possible candidate is FAN1, which
encodes a DNA repair enzyme. Rare nonsynonymous
variants have been found in this gene among individuals
with ASD or schizophrenia.40 Consequently, other genes
in the 15q13.3 microdeletion could contribute to disease
pathogenesis.
Here, we used multiple in silico, in vivo, and in vitro
strategies to dissect the cellular phenotypes and critical
loci that contribute to the 15q13.3 microdeletion syn-
drome. By using the Df(h15q13)/þ heterozygous mouse
model, RNA sequencing, signaling pathway analysis, and
neuronal morphology analysis, we discovered that devel-
oping cortical excitatory neurons have deficiencies in
dendrite and synapse growth (Figure S2). We concurrently
identified candidate gene(s) within this syndromic region
contributing to these phenotypes by applying develop-
mental human brain expression (transcriptome and
proteome) data analysis together with whole-genome
and -exome sequencing data from individuals with neuro-
developmental disorders and ASD.41 These analyses iden-
tified a strong candidate gene, OTUD7A, within the
15q13.3 microdeletion syndrome region, which encodes
a putative deubiquitinating enzyme that localizes to den-
dritic spine compartments and has a protein-protein co-
expression network that includes synaptic and dendritic
signaling pathways. We biologically validated OTUD7A
and found that re-expressing OTUD7A WT into cortical
neurons from Df(h15q13)/þ mice rescued the dendritic
spine defects. However, a mutant OTUD7A harboring an
ASD-linked de novo exonic mutation was unable to rescue
these defects. Furthermore, we found that both OTUD7A
and CHRNA7 contribute to the dendrite outgrowth de-
fects. Our data identify OTUD7A as a candidate gene
that contributes to abnormalities in cortical neuron
dendritic and spine development and a critical gene in
the phenotypic manifestation of the 15q13.3 microdele-
tion syndrome.Material and Methods
RNA Sequencing and Differential Expression Analysis
mRNA was extracted from E16, P21, and adult (P63) mouse
cortical brain tissue using Trizol LS reagent (ThermoFisher Scienti-
fic). Two WT and two Df(h15q13)/þ mice were used for each time
point (12 mice total). All postnatal mice used for transcriptome
analysis were male whereas sex was undetermined for embryonic
mouse brain samples. Quality of total RNA samples was checked
on an Agilent Bioanalyzer 2100 RNA Nano chip following
Agilent Technologies’ recommendation. We have measured the
concentration by Qubit RNA HS Assay on a Qubit fluorometer
(ThermoFisher). The library preparation for RNA was performed
following the Illumina Stranded mRNA Library Preparation
protocol. In brief, 500 ng of total RNA was used as the input mate-
rial and enriched for poly(A) mRNA, fragmented into the 200- to
300-base range for 4 min at 94C and converted to double
stranded cDNA, end-repaired, and adenylated at the 30 to create
an overhang A to allow for ligation of Illumina adapters with an
overhang T; library fragments were amplified under the followingn Journal of Human Genetics 102, 278–295, February 1, 2018 279
conditions: initial denaturation at 98C for 10 s, followed by 10 cy-
cles of 98C for 10 s, 60C for 30 s, and 72C for 30 s, and finally an
extension step for 5 minutes at 72C; at the amplification step,
each sample was amplified with different barcoded adapters to
allow for multiplex sequencing. To check the size fragment, 1 mL
of the final RNA libraries was loaded on a Bioanalyzer 2100 DNA
High Sensitivity chip (Agilent Technologies); RNA libraries were
quantified by qPCR using the Kapa Library Quantification
Illumina/ABI Prism Kit protocol (KAPA Biosystems). Libraries
were pooled in equimolar quantities and paired-end sequenced
on an Illumina HiSeq 2500 platform using a High Throughput
Run Mode flowcell and the V4 sequencing chemistry following
Illumina’s recommended protocol to generate paired-end reads
of 126 bases in length.
We used TopHat42 to align the read and conducted expression
analysis for each gene through reads per kilobase of transcript
per millionmapped reads (rpkm) computation. To compute global
differential expression (DE) analysis for each of the three time
points—E16, P21, and adult (P63)—we conducted comprehensive
DE analysis using a Bioconductor package named edgeR.43 Differ-
ential expression was computed against control expression for
each of the three time points separately and a gene was considered
differentially expressed for a time point only if p < 0.0001 and
FDR < 0.05.Microarray and Sequencing Data
Microarray data were obtained for 38,325 ASD-affected and devel-
opmental delay (DD)-affected case subjects from four large sour-
ces (Table S3). The first dataset is comprised of 1,026 samples diag-
nosed primarily with ASD and genotyped with high-resolution
microarrays (Illumina 1M). The other three other datasets
comprised case subjects with developmental delay. The first of
these includes 9,322 samples recruited from USA by a private
company (Lineagen Inc.) and the data were generated using
high-resolution Affymetrix Cytoscan HD in conjunction with
the Chas algorithm. The second dataset comprised 10,619 DD-af-
fected case subjects from two major clinics in Ontario, Canada.
For the first and second datasets, ethical clearance was obtained
from The Hospital for Sick Children’s institutional ethical board.
The third dataset is from a published dataset of 17,358 case sub-
jects with DD in USA, primarily from a private diagnostic com-
pany which used the international standards for cytogenomic
arrays (ISCA) for variant classification.44 We have preprocessed
22,241 control samples from seven different sources that were
recruited as population control subjects.44–50 For both case and
control subjects, we focused on deletions with >50% reciprocal
overlap with the 15q13.3 microdeletion region (BP4-BP5). Gene-
specific deletions and atypical variants that were larger and over-
lapped with 15q13.3 were also kept for fine mapping. To identify
de novo mutations within the 15q13.3 locus, we analyzed pub-
lished whole-exome and -genome sequencing data from autism
spectrum disorder cohorts51–53 and a homogeneous population
control.54 Variants were validated using Sanger sequencing as
described in Yuen et al.53 Consent was obtained from all human
participants, as approved by the Research Ethics Boards at The
Hospital for Sick Children, McMaster University, and Memorial
Hospital.Critical Exon and Protein Expression Analysis
Whole-genome sequencing data from the 1000 Genomes Project
was used to compute the burden of rare missense and loss-of-280 The American Journal of Human Genetics 102, 278–295, Februarfunction mutations for each exon. Furthermore, exon-level
expression data from RNA sequencing were obtained for devel-
opmental human brain tissues (prenatal and postnatal postmor-
tem donors) from the BrainSpan project and ten other human
tissues. The analysis to identify brain-specific critical exons has
been described in Uddin et al.41 where 10% of genes within
the genome were shown to be brain critical and this specific
group of genes is significantly enriched for de novo mutations
in autism probands but not in unaffected siblings or in popula-
tion control subjects. In brief, to classify critical exons, we
computed the expression level from RNA-sequencing data
from developmental human brain for each exon and classified
high and low based on the 75th percentile of the entire dataset.
An exon was classified as critical exon if it is highly expressed in
a tissue and the burden of deleterious mutation is low. A critical
exon was classified as brain specific if critical only for brain and
not other tissues. We obtained a brain-specific protein module
from Uddin et al.,1 where a comprehensive weighted gene co-
expression network analysis (WGCNA) was conducted on the
high-resolution protein mass-spectrometry dataset from devel-
opmental human tissues (24 different human tissues, each
pooled from 3 post-mortem donors which includes 17 adult
and 7 prenatal samples). For the 15q13.3 microdeletion syn-
drome locus, OTUD7A is the only gene within the brain-specific
protein module and we have extracted the first-degree neighbors
from the module. An over-representation analysis was con-
ducted with gene sets using a Fisher exact test and p value was
corrected for multiple tests.
To produce gene level expression information, we normalized
the entire protein expression level data from 24 different human
tissues and quantified the 75th percentile of the expression value
from the entire data. Expression for a gene was considered high
if it was above the 75th percentile, and low otherwise. For gene-
level RNA-seq expression data, we followed the same protocol as
the protein expression data for consistency.Geneset Enrichment Analysis and Visualization
We conducted a comprehensive geneset enrichment analysis on
RNA-seq differentially expressed genes and for the first-degree
neighbor proteins for OTUD7A that were extracted from the
blue protein module. We manually curated 2,848 gene sets from
the gene ontology (GO) (R package, v.2.8.0), pathways from the
National Cancer Institute at the National Institutes of Health
(NCI-NIH), Kyoto Encyclopedia of Genes and Genomes (KEGG)
(May 30, 2013), and Reactome databases. Gene sets were consid-
ered significant after Benjamini-Hotchberg false discovery rate of
0.05. To visualize network datasets, we used Cytoscape plugins
using v.3.2.0.Animals
Df(h15q13)/þ mice were generated by Taconic Artemis as
described in Fejgin et al.25 Animals were bred, genotyped, and
housed at the Central Animal Facility at McMaster University.
All procedures received the approval of the Animal Research
Ethics Board (AREB). Genotypes were identified during breeding
by PCR of ear notches, and three WT females were bred with 1
Df(h15q13)/þmale per breeding cage. The use of onlyWT females
for breeding was performed tominimize effects of potential differ-
ences in the embryonic environment and/or mothering of the
Df(h15q13)/þ females compared toWT females. To obtain cortical
cultures, WT females were timed-bred with Df(h15q13)/þ malesy 1, 2018
and males were removed when a plug was observed, indicating
copulation. At E16, mothers were sacrificed and litters were
collected. Animals of appropriate genotype were included, and
any animals with unclear genotypes were excluded from
experiments.Cell Culture and Transfection
Primary cortical neurons were cultured as follows. Cortices were
dissected out of WT and Df(h15q13)/þ mouse embryonic brains
at E16. Each brain was cultured individually. Dissociation was
aided by incubation in 0.3 mg/mL Papain (Worthington
Biochemical)/400 U/mL DNase I (Invitrogen) in 13 Hanks Buff-
ered Saline Solution (HBSS) for 20 min at 37C, followed by light
trituration. Cells were seeded onto 0.1 mg/mL poly-D-lysine (BD
Sciences)/3.3 mg/mL Laminin (Sigma)-coated coverslips (Matsu-
nami) in 12-well plates in plating media containing Neurobasal
medium, 10% fetal bovine serum, 1% penicillin/streptomycin,
and 2 mM L-glutamine (Invitrogen). After 1.5 hr, media was
changed to serum-free feeding media containing Neurobasal me-
dium, 2% B27 supplement, 1% penicillin/streptomycin, and
2 mM L-glutamine. At DIV2-4, cultures were treated with 1 mM
Cytosine b-D-arabinofuranoside hydrochloride (Ara-C) (Sigma)
to inhibit glial cell proliferation. Cultures were maintained at
37C, 5% CO2. All media components were from GIBCO unless
otherwise specified. Transfections were performed at DIV7 using
Lipofectamine LTX and Plus reagents (Invitrogen) according to
the manufacturer’s instructions. HEK293FT cells (Invitrogen)
were grown under standard cell culture conditions and trans-
fected with plasmids using Lipofectamine 2000 according to the
manufacturer’s protocol (Invitrogen). HEK293FT cells were used
for ease of plasmid expression and have not been tested for
Mycoplasma contamination.In Utero Electroporation
Timed-pregnant WT female and Df(h15q13)/þ male mice were
anesthetized by isoflurane (gas). The uterine horns were exposed,
and FLAG-pcDNA control or FLAG-OTUD7A WT plasmids with
pCAG Venus contructs (4:1 ratio) mixed with Fast Green were
injected into the lateral ventricles of E16 embryos. 5 current pulses
(conditions: 950 ms pulse, 50 ms interval, 36V) were delivered
across the head of the embryos. Litters were born and sacrificed
by perfusion at P22. Mice were anesthetized by isoflurane gas
followed by intraperitoneal injection of sodium pentobarbitol.
This was followed by perfusion with lactate ringers solution and
then 4% PFA. Following perfusion, brains were harvested and
post-fixed in 4% PFA for 48 hr at 4C. Mice were genotyped as
described, and brains were sectioned using a vibratome (Leica) at
50 mm thickness (coronal).Antibodies and Constructs
The following primary antibodies were used in this study. Mouse
anti-FLAG (Sigma F3165; IF 1:2,000; western blotting 1:2,000),
rabbit anti-b-actin (Cell Signaling 4970; western blotting
1:2,000), and anti-rabbit PSD95 (Cell Signaling Technologies
D27E11; IF 1:200). All secondary antibodies (anti-rabbit cy5,
anti-mouse cy3; Jackson ImmunoResearch; IF 1:500, anti-rabbit-
HRP, anti-mouse-HRP; GE Life Sciences; IB 1:5,000) were raised
in donkey.
pCAGIG-Venus was provided by Dr. Zhigang Xie (Boston
University, MA). The FLAG-OTUD7A WT was amplified from
a pCMV6_FLAG-WT-OTUD7A construct (Origene, RC213015,The AmericaGenBank: NM_130901) and cloned into the pcDNA3.3 vector
between EcoRI and KpnI. pcDNA3.3_FLAG-OTUD7A p.Asn492_
Lys494del plasmid was generated using In-Fusion cloning
kit. FLAG-CHRNA7, FLAG-FAN1, and FLAG-KLF13 were amplified
from a pCMV6_FLAG-CHRNA7 (Origene, RC221382, GenBank:
NM_000746), pCMV6_FLAG-FAN1 (Origene, RC224249, GenBank:
NM_014967), and pCMV6_FLAG-KLF13 (Origene, RC200805,
GenBank: NM_015995) and cloned into the pcDNA3.3 vector using
In-Fusion cloning kit.Immunocytochemistry
On DIV14, cells on glass coverslips were fixed with 4% formalde-
hyde in PBS for 20 min at room temperature. Cells were washed
in PBS, followed by blocking in blocking/permeabilization
solution consisting of 10% Donkey Serum (Millipore) and 0.3%
Triton X-100 (Fisher Scientific) in PBS for 1 hr at room tempera-
ture. Incubation in primary antibodies was performed at 4C
overnight. Cells were then washed in PBS, followed by incubation
with secondary antibodies in 50% blocking/permeabilization
solution at room temperature with gentle agitation for 1.5 hr. Cells
were then washed in PBS and were mounted on VistaVision glass
microscope slides (VWR) using Prolong Gold antifade reagent (Life
Technologies). Images were acquired using a Zeiss LSM700
confocal microscope.Golgi Staining
Golgi staining was performed on mouse brains from P28 male
mice using a commercial kit and protocol (FD Rapid GolgiStain
Kit, FD NeuroTechnologies, Inc.). Briefly, whole mouse brains
were removed and washed with Milli-Q water. The brain was
immersed in impregnation solution for 8 days. Following impreg-
nation, brains were rinsed twice with water and incubated for
72 hr with Solution C. Brains were then removed and incubated
in 30% sucrose/PBS for 24 hr in the dark. Using a vibratome
(Leica), brain slices were cut at 150 mm thickness and mounted
onto 3% gelatin-coated SuperFrost Plus microscope slides
(ThermoFisher). Sections were incubated in staining solution for
10 min, washed with Milli-Q water, dehydrated with EtOH, and
cleared with xylene (Sigma). Stained brain slices were imaged
using Zeiss Axiocam ICm1 microscope camera. Z stacks were ac-
quired at 1 mm intervals for sholl analysis and 0.28 mm intervals
for spine analysis. Images were processed using ImageJ software
(Sholl Analysis plugin).Morphological Analyses
Images were processed and analyzed with ImageJ 1.44 software.
Sholl analysis was performed using the Sholl analysis plugin in
ImageJ. This plugin was used to make concentric circles
increasing at a constant radius of 10 mm and to count the number
of dendritic intersections. Neuron tracing was performed using
the NeuronJ plugin for ImageJ 1.44. Spine density was calculated
by visually counting all protrusions from a dendrite within a
15–25 mm distance starting at a secondary branch point. One
to three dendritic segments were analyzed per neuron. Maximal
spine head width (HW), neck width (NW), length (L), and neck
length (NL) were measured for each dendritic protrusion using
the segmented line tool in ImageJ. Spines were defined as
follows: stubby (L < 1 mm), mushroom (1 % L % 5 mm;
HW% 23 NW), or thin (1% L% 5 mm;WH% 23 NW). The pro-
portion of each spine type was calculated by dividing the number
of spines in each spine category (mushroom, thin, and stubby)n Journal of Human Genetics 102, 278–295, February 1, 2018 281
Figure 1. Overview of the 15q13.3
Microdeletion and CHRNA7/OTUD7A
Overlapping Deletion
Schematic diagram showing the location
of the human 15q13.3 locus and all ten
genes within the 1.5 Mb BP4-BP5 deletion.
Smaller deletions (red bar) are found
within the BP4-BP5 region overlapping
CHRNA7 and/or OTUD7A, modified from
Lowther et al.24 The experimental work-
flow of the current study is presented
below the schematic.by the total number of spines within the dendritic segment. For
analyses on Golgi-stained brains, 40 neurons from 4 brains per
condition were used for sholl analysis and 40 dendritic segments
from 4 mouse brains per condition were used for spine analysis.
For IUE experiments, 21–23 neurons from 3 brains per condition
were used for sholl analysis, and 30 dendritic segments from
3 brains per condition were used for spine analysis. For in vitro
analyses, 21–50 neurons were used from 3–4 biological replica-
tions (mouse litters) for sholl analysis, and 20–36 dendritic seg-
ments from 3–5 biological replications (mouse litters) for spine
analysis.
Quantitative PCR
To measure postnatal developmental RNA expression of OTUD7A
in the mouse brain, we obtained whole-brain samples of P0, P7,
P14, P21, P28, and P63 WT C57BL/6 mice. Total RNA was
extracted using TRIzol LS Reagent (Thermo Fisher Scientific),
followed by cDNA synthesis using the qScript cDNA synthesis
kit according to manufacturer instructions (Quanta Biosciences).
Primers and probes were designed and selected using the Universal
Probe Library (UPL) Probefinder software for mouse (Roche).
Quantitative PCR was performed using the Perfecta qPCR282 The American Journal of Human Genetics 102, 278–295, February 1, 2018Supermix (Quanta Biosciences) and UPL
probe #50 (OTUD7A) or UPL probe #52
(GAPDH). Data represented as levels of
OTUD7A normalized to GAPDH levels.
Western Blotting
Western blotting was performed using
standard protocols. Briefly, HEK293FTcells
were lysed in lysis buffer (150 mM NaCl,
1% Triton X-100, 50 mM Tris-Cl, and
cOmplete mini protease inhibitor cocktail
(Roche). 20–30 mg of sample was loaded
into a 10% Tris-Glycine gel and transferred
to a PVDF membrane (Bio-Rad). Mem-
branes were blocked for 1 hr in 3% milk
in 13 TBST, incubated with primary anti-
body overnight at 4C, then with second-
ary antibody (donkey anti-mouse or anti-
rabbit HRP, GE Healthcare) for 1 hr at
room temperature before exposure using
a ChemiDoc MP system (Bio-Rad).
Statistical Analysis
Data are expressed as mean5 SEM. Amin-
imum of three mice per condition or threemouse litters for in vitro culture experiments, was used for statistical
analysis. Blinding was not performed.We used the Student’s t test,
one-way ANOVA with post hoc Tukey’s test, and two-way ANOVA
in GraphPad Prism 6 statistical software for statistical analyses.
p values in the figure legends are from the specified tests, and
p < 0.05 was considered statistically significant.Results
Df(h15q13)/þ Mice Show Defects in Forebrain
Development Including Abnormalities in Dendritic
Spines and Dendrite Growth
To study the 15q13.3 microdeletion (Figure 1), we utilized
the heterozygous BP4-BP5 mouse model (Df(h15q13)/þ).25
We examined temporal gene expression (using RNA
sequencing) in cortical brain tissue from Df(h15q13)/þ
and WT mice at three stages: prenatal (embryonic day
16; E16), early postnatal (postnatal day 21; P21), and adult
(P63) (Figures S1A and S1B and Table S1). We identified
66 genes with significant (p < 0.0001 and FDR < 0.05)
differential expression from the three developmental time
points.Mtmr10,Otud7a, Klf13, Fan1, and Chrna7 displayed
significant differential expression (DE) in all periods
(Trpm1 is not expressed in the brain, and miR211 was not
detected because samples were not enriched for small
RNAs during sample preparation) (Figure S1A), demon-
strating that the heterozygosity of gene expression persists
into adulthood. Interestingly, we found that differential
gene expression was most pronounced (2-fold) at post-
natal time points, P21, and adulthood (when spine and
synapse development is peaking). We conducted extensive
gene enrichment analyses for all differentially expressed
genes by using 2,848 gene sets with defined biological
pathways in KEGG, GO, NCI-NIH, and Reactome data-
bases. The most significant enrichment across all time
points was observed for prenatal organ development
(p < 2.9 3 1005, significant after Benjamini-Hochberg
correction) and forebrain development (p < 6.8 3 105)
(Figure S1C and Table S2). The significant enrichment of
the forebrain development pathway in the WT versus
Df(h15q13)/þ comparison suggests that cortical develop-
ment is disrupted by the microdeletion.
We next focused on postnatal cortical (forebrain) devel-
opment in Df(h15q13)/þ mice because of our transcrip-
tional data and previous studies that identified abnormal-
ities in excitatory neuron development.55–58 Therefore, we
measured dendritic spine morphology and dendrite
growth in vivo on Golgi-Cox-stainedWTandDf(h15q13)/þ
mouse brains. We analyzed cortical neurons in layers 2/3
of the prefrontal cortex (PFC) of male P28 Df(h15q13)/þ
and age/sex-matched WT mice. We found that in
Df(h15q13)/þ prefrontal cortex, there was a small but
significant (p < 0.01) reduction in spine density and
mature mushroom-shaped spines (Figures 2A and 2B).
Df(h15q13)/þ mice also displayed a significant (p < 0.05)
reduction in spine length and spine neck length
(Figure S2A). Dendritic arborization was measured using
Sholl analysis59 and revealed that Df(h15q13)/þ mice
showed decreased arborization in layer 2/3 PFC neurons
compared to WT mice (Figures 2C and 2D). Since these
findings were obtained in vivo, it is difficult to determine
whether they are cell autonomous. Therefore, we cultured
cortical neurons from littermate Df(h15q13)/þ and WT
mice, transfected with a Venus fluorescent reporter,
and analyzed neurons at 14 days in vitro (DIV14).
Df(h15q13)/þ neurons also showed a significant reduction
in the density of dendritic spines and spine length (Figures
2E, 2F, and S2B), as well as a decrease in mature mush-
room-type spines (p < 0.05) and increase in immature
stubby-type spines (p < 0.01) (Figure 2G), replicating
many of the in vivo phenotypes. In addition, there
was a significant decrease in dendritic arborization in
Df(h15q13)/þ neurons compared to WT littermates (Fig-
ures 2H and 2I). The spine and dendrite phenotypes in
Df(h15q13)/þ observed in vitro were stronger than in vivo,
suggesting some level of compensation, similar to previ-
ous reports.3,60The AmericaOTUD7A Is a Candidate Driver Gene in the 15q13.3
Microdeletion
We further assessed the pathogenicity of the 15q13.3
microdeletion by using large datasets to compile all avail-
able published and unpublished case subjects (Table S3).
In addition, clinical microarray data from 38,325 case sub-
jects with a range of neurodevelopmental disorders were
examined to identify the frequency of 15q13.3 deletions
(chr15: 30910306–32445407 [hg19], encapsulating BP4
and BP5). Stringent CNV calling parameters were
applied (minimum of 5 probes, minimum of 2 algorithms,
>30 kb in length) on the clinical microarray data, facili-
tating the discovery of 156 individuals with 15q13.3
microdeletions impacting the typical BP4-BP5. Among
these microdeletions, 148 were detected in case subjects
with broad developmental phenotypes and 8 in case
subjects with a primary diagnosis of ASD (Figure S3A). In
contrast, we identified only one BP4-BP5 deletion within
a control population of 22,241 individuals (Figure S3A).
The enrichment of 15q13.3 microdeletions within
neurodevelopmental disorder-affected and ASD-affected
case subjects (0.4% combined in NDD and ASD case
subjects; 0.004% in control subjects) is highly significant
(p < 1.30 3 1029). Together, these data re-confirm that
the 15q13.3 microdeletion is strongly associated with
neurodevelopmental disorders.16,61
We then applied three approaches to narrow down the
potential contributing gene(s) from the ten genes present
in BP4-BP5. First, we determined whether there are smaller
deletions within BP4-BP5 that are associated with neurode-
velopmental disorders. We delineated the minimal region
(530 kb in size) of overlap from our clinical microarray
sample and found that only two genes (CHRNA7 and
OTUD7A) are associated with an atypical smaller CNV.
This has been reported previously, but it is particularly
noteworthy that at least 43 overlapping deletions encom-
passing CHRNA7 also impacted OTUD7A20,24 (Figure 1).
Furthermore, since 52 microdeletions encompassing
CHRNA7 are found within our control samples (compared
to zero smaller deletions in controls within OTUD7A), this
also implicates other genes within the CNV. In further
support of this, we identified a 5-year-old female, previ-
ously unreported in the literature, with global develop-
mental delay who possessed a genetic deletion that
spanned BP4-BP5 including OTUD7A but not CHRNA7
(Figure S3B). Similarly, a duplication breakpoint that does
not involve CHRNA7 has also been recently reported in a
female patient with atypical Rett syndrome who is nega-
tive for an MECP2 mutation.62 Taken together, these data
suggest that genes other than CHRNA7, such as OTUD7A,
may contribute to the 15q13.3 microdeletion syndrome.
We next investigated DNA sequence-level mutations
in the ten genes within the microdeletion among individ-
uals with a neurodevelopmental disorder but who did
not have a 15q13.3 microdeletion. We focused on de
novo mutations, given their established role in pathoge-
nicity.41,51–53,63–66 We investigated whole-genomen Journal of Human Genetics 102, 278–295, February 1, 2018 283
Figure 2. Df(h15q13)/þ Mice Have Defects in Dendritic Spine Development and Neuronal Morphology
(A) Golgi-stained dendritic spine images (left) and spine density analysis (right). Df(h15q13)/þmice show a decrease in spine density in
layer II/III PFC neurons. WT, n ¼ 40 dendritic segments, 22 neurons; Df(h15q13)/þ, n ¼ 40 dendritic segments, 26 neurons, 4 mice per
condition, Student’s t test, **p < 0.01, t(78) ¼ 2.846. Scale bar ¼ 5 mm.
(B)Df(h15q13)/þmice show a decrease in PFCmushroom spines (left).WT, n¼ 40 dendritic segments, 22 neurons;Df(h15q13)/þ, n¼ 40
dendritic segments, 26 neurons, 4 mice per condition, Student’s t test, *p < 0.05, t(78) ¼ 2.403, t(78) ¼ 0.1312, t(78) ¼ 1.673.
(C) Traces of P28 WT and Df(h15q13)/þ Golgi-stained layer II/III prefrontal cortical (PFC) neurons.
(D) Sholl analysis (left) and the total number of intersections (right).Df(h15q13)/þmice show a decrease in dendrite growth in layer II/III
PFC neurons. n ¼ 40 neurons, 4 mice per condition, two-way ANOVA followed by Tukey’s post hoc test, ***p < 0.001, F(9, 780) ¼ 109.2,
t(78) ¼ 3.449.
(E) Dendritic spine images from WT and Df(h15q13)/þ cultured neurons (scale bar ¼ 5 mm).
(F) Spine density measurements in cultured neurons. Spine density is decreased in Df(h15q13)/þ cultured cortical neurons. WT, n ¼ 32
dendritic segments from 12 neurons; Df(h15q13)/þ, n ¼ 32 dendritic segments from 15 neurons, 3 cultures, Student’s t test, *p < 0.05,
t(62) ¼ 2.311.
(G) Dendritic spine classification inWTandDf(h15q13)/þ neurons. In Df(h15q13)/þ cultured cortical neurons, the proportion of mush-
room-type spines is decreased (left) and the proportion of stubby type spines is increased (right). WT, n¼ 32 dendritic segments from 12
neurons; Df(h15q13)/þ, n ¼ 32 dendritic segments from 15 neurons, 3 cultures, Student’s t test, *p < 0.05, **p < 0.01, t(62) ¼ 2.007,
t(62) ¼ 0.1383, t(62) ¼ 2.875.
(H) DIV14 WT and Df(h15q13)/þ cultured cortical neurons expressing Venus (scale bar ¼ 50 mm).
(I) Sholl analysis of cultured cortical neurons. Dendrite growth is decreased in Df(h15q13)/þ neurons. n ¼ 50 neurons, 3 cultures, two-
way ANOVA followed by Sidak post hoc test, ***p < 0.001, F(14, 1470) ¼ 85.55. Error bars represent SEM.sequencing data (n ¼ 84 ASD quad families53) and
exome-sequencing data (n ¼ 5,953 ASD trios51,52) and
discovered 8 de novo mutations impacting regions in the
BP4-BP5 interval. Three of these mutations impacted
OTUD7A, one impacted MTMR10, one impacted TRPM1
(Table 1, case 2, GenBank: NM_001252024.1; c.2382C>G
[p.Phe794Leu]), and the remainder were intergenic de284 The American Journal of Human Genetics 102, 278–295, Februarnovo mutations. Among the de novo OTUD7A mutations
specifically, the first is an exonic de novo 9 bp non-frame-
shift deletion (Table 1, case 3, GenBank: NM_130901.2;
c.1474_1482del [p.Asn492_Lys494del]), in an ASD-
affected proband and their affected sibling (Figures 3A,
S3D, and S3E, and Table 1). The second and third are
both intronic, one a de novo indel (2 bp deletion) observedy 1, 2018
Table 1. Individual ASD-Affected Case Subjects with De Novo Mutations Found near or within OTUD7A
ASD Cases Chromosome Nucleotide-Level Change-HGVS Format Protein-Level Change Seq-Type Variants Gene/Nearby Genes
Case 1 15 XM_005254506.1; c.93617A>G – intronic MTMR10
Case 2 15 NM_001252024.1; c.2382C>G p.Phe794Leu missense TRPM1
Case 3 15 NM_130901.2; c.1474_1482del p.Asn492_Lys494del exonic-indel OTUD7A
Case 4 15 NC_000015.9; g.31557488A>C – intergenic KLF13
Case 5 15 NC_000015.9; g.32309599_32309610del – intergenic-indel OTUD7A, CHRNA7
Case 6 15 NC_000015.9; g.32309599_32309610del – intergenic-indel OTUD7A, CHRNA7
Case 7 15 XM_005254201.1; c.223þ11014A>G – intronic OTUD7A
Case 8 15 NM_130901.1; c.1150þ935del – intronic-indel OTUD7Ain an ASD-affected proband and the other an intronic
de novo single-nucleotide mutation in an ASD-affected
proband (Table 1). One of the intergenic de novomutations
was identified in two ASD-affected siblings between
OTUD7A and CHRNA7 (cases 5 and 6 in Table 1);
genome-wide, no other pathogenic exonic mutations or
CNVs were identified in either of these affected siblings.
Interestingly, the intergenic mutation between OTUD7A
and CHRNA7 occurs in the binding site of the transcription
factor, enhancer of zeste 2 polycomb repressive complex
subunit 2 (EZH2) (Figure S4). EZH2 (MIM: 601573) has
previously been implicated in dendrite growth,67
which raises the hypothesis that EZH2 regulates OTUD7A
expression; however, further investigation is required to
investigate the intergenic mutations. In contrast, no de
novo mutations within OTUD7A were identified from
whole-genome sequencing of 250 Dutch trio control
samples54 or exome sequencing of the unaffected siblings
of ASD-affected probands (from a family dataset of 5,205
individuals).52 The identification of de novo mutations
either within or near OTUD7A is further evidence in
support of OTUD7A as a major critical gene in the
15q13.3 microdeletion syndrome.
In our final approach, we assessed the exons of human
genes for relevancy in neurodevelopment according to
their population-level deleterious mutational burden in
concert with brain mRNA expression (from RNA-
sequencing data), earmarking those exons with a low
mutational burden and high mRNA expression only in
the developing human brain as being ‘‘brain critical.’’1,41
This analysis identified FAN1 and OTUD7A as genes
bearing critical exons, with OUTD7A having a higher ratio
of brain critical exons than FAN1 (Figure 3C). FAN1 was
recently suggested to be a susceptibility gene in the
15q13.3 microdeletion based on the identification of an
enrichment of small nucleotide variants (SNVs) in ASD
and SCZ populations.40 However, in our analysis, we did
not identify de novo mutations in FAN1 or overlapping de-
letions containing this gene and therefore did not pursue it
further. To complement the critical exon analysis, we also
examined the tolerance of loss-of-function (pLI) mutations
of each of the 15q13.3 genes (a measure of the probabilityThe Americathat a given gene is extremely intolerant of loss-of-func-
tion variation) from the exome aggregation consortium
(ExAC) database.68 Comparison of the genes in the
15q13.3 microdeletion (no data were available for
CHRNA7) revealed that OTUD7A possessed the most
constrained gene scores (pLI ¼ 0.97 and Z ¼ 5.92)
(Figure 3D), supporting its important evolutionary role in
development.
To investigate the expression patterns of the genes
within the BP4-BP5 deletion in the brain, we conducted
qRT-PCR analysis of 8 genes (except KLF13 and miR-211;
LOC100288637 was not detected) in 12 human tissues.
For each gene, primers were designed targeting the exons
that are common in all transcripts and our qRT-PCR anal-
ysis revealed that OTUD7A was the only gene that
displayed a brain-specific mRNA expression pattern
compared to other tissues (Figures 3B and S3C). This is
similar to the expression profile of OTUD7A in the GTeX
database. Furthermore, the BrainSpan database for human
developmental brain expression shows that many
OTUD7A exons are expressed above the 75th percentile of
the total brain expression dataset (Figure S3F). KLF13 is
notable because it has higher brain expression than
OTUD7A in these databases; however, upon further exam-
ination it is largely driven by one exon (Figure S3F), and its
expression is not brain specific, which is evident in the
critical-exon analysis.
We also determined the protein co-expression network
for OTUD7A in the brain using recently published human
tissue protein-level data.69 To identify a core set of proteins
having an important role in brain development, we
analyzed protein data from 24 human tissues (each pooled
from 3 post-mortem samples) including 17 adult and 7
prenatal samples that were run through high-resolution
Fourier transform mass spectrometers for fragmenta-
tion.69 Weighted gene co-expression network analysis
(WGCNA) analysis was used to identify 23 unbiased and
independent protein modules. After rigorous gene set
enrichment analysis (see STAR Methods), one of the
modules was chosen for further analysis, as it was brain-
specific and significantly associated with neurodevelop-
ment and comprised of 2,484 proteins.70 Strikingly,n Journal of Human Genetics 102, 278–295, February 1, 2018 285
Figure 3. Identification of OTUD7A as a Driver Gene of the 15q13.3 Microdeletion
(A) Schematic of the human OTUD7A protein showing the exonic 9 bp mutation (de novo p.Asn492_Lys494 deletion in the protein)
found in an ASD proband and affected sibling (proband is case 3 in Table 1). Themutation is located in the nuclear localization sequence
(NLS) of OTUD7A.
(B) OTUD7AmRNA expression relative to ACTB in various human tissues. OTUD7A is enriched in the brain, with highest expression in
the frontal cortex.
(C) Ratio of brain critical exons in nine genes within the 15q13.3 microdeletion region. FAN1 and OTUD7A contain brain critical exons,
with OTUD7A showing a higher ratio than that of FAN1.
(D) OTUD7A has the highest pLI (a score that indicates the probability that a gene is intolerant to a loss-of-function mutation) value
compared to the other genes in the 15q13.3 critical region. The left y axis represents the number of observed LOF mutations within
the ExAC population scale dataset and the right y axis shows the computed pLI score.
(E)OTUD7AmRNA expression in themouse brain is low in early postnatal life, increases into adolescence, and remains stable into adult-
hood (n ¼ 2 technical replicates).
(legend continued on next page)
286 The American Journal of Human Genetics 102, 278–295, February 1, 2018
WGCNA analysis identified OTUD7A as being the only
gene within 15q13.3 microdeletion that was part of the
brain-specific protein module. This is because the other
15q13.3 genes’ protein products did not have brain-spe-
cific expression. We identified 616 strongly connected
(top 25th percentile) first-degree neighbor genes for
OTUD7A within the brain-specific protein module. A
comprehensive enrichment analysis was conducted,
which determined that these OTUD7A neighboring genes
are highly enriched for targets of FMR1 (Fragile X Mental
Retardation 1), many of which are known to play a role
at the synapse, as well as genes harboring ASD de novomu-
tations (Figure 3F). We performed a comprehensive gene
set enrichment analysis to decipher the pathways and
biological relevance of OTUD7A neighbor genes. The three
most significant associations were observed with synapse
(GO:0045202) (p < 1.1 3 1082, Benjamin-Hochberg
corrected), synaptic component (GO:0044456) (p <
9.92 3 1072), and neuron projection (GO: 0043005)
(p < 9.96 3 1071) (Table S4). These co-expression
networks align with the potential involvement ofOTUD7A
in the spine and dendrite abnormalities observed in
Df(h15q13)/þ mice. Furthermore, the collective data indi-
cate thatOTUD7A is the only gene in the 15q13.3microde-
letion that has brain-specific expression, contains critical
exons, and is interconnected with a brain-specific synaptic
signaling network linked to ASD.
Expression and Localization of OTUD7A in Neurons
We utilized WT and Df(h15q13)/þ mice to investigate the
biological function of Otud7a in the brain and to test our
hypothesis that OTUD7A is a critical gene in the 15q13.3
microdeletion. We first analyzed the expression of Otud7a
mRNA in the developingWTmouse brain and observed an
expression profile similar to the developing human brain,
with an increase in expression during early postnatal
stages when dendrite and spine development are impor-
tant (Figure 3E) and similar to the RNA-sequencing data
(Figure S1A). To determine the localization of OTUD7A
in neurons, we transfected a FLAG-tagged humanOTUD7A
(FLAG-OTUD7A WT) construct in cultured WT mouse
cortical neurons and analyzed FLAG levels at DIV14, since
no validated antibodies against OTUD7A are available.
This experiment revealed that OTUD7A has a punctate
localization pattern and is restricted to the soma and den-
drites in Venus-transfected neurons (Venus is used for visu-
alization) (Figure 3G). A very similar protein localization
pattern was also independently reported by a companion(F) OTUD7A protein co-expression network module. Weighted gene
data shows that 616 genes are highly co-expressed with OTUD7A (top
harbor known ASD de novo mutations (left, red dots) and 30% of hig
(G) DIV14 WT mouse cortical neurons co-expressing Venus and FLA
co-localized with PSD95 in dendrites and dendritic spines. Arrow
bars ¼ 20 mm, top; 5 mm, bottom).
(H) Quantification of FLAG-OTUD7A and PSD95 puncta co-locali
p.Asn492_Lys494del overexpression (OTUD7AWT, n¼ 18 neurons;O
t test, t(31) ¼ 0.7813). Error bars represent SEM.
The Americastudy in this issue of AJHG.37 Furthermore, we detected a
fraction of FLAG-OTUD7A puncta in dendritic spines
that co-localized with PSD95, a postsynaptic marker of
mature excitatory synapses (Figures 3G and 3H). These
data reveal that Otud7a is expressed in the brain and can
localize to dendritic and synaptic compartments in cortical
neurons.
Rescue of Spine and Dendrite Phenotypes in
Df(h15q13)/þ Excitatory Neurons by OTUD7A
We hypothesized that the reduced expression of Otud7a in
Df(h15q13)/þ heterozygous neurons mediated the den-
dritic spine and dendrite growth phenotypes, and
increasing OTUD7A expression in these neurons would
rescue the deficit. To test this, we co-transfected Venus
and FLAG-OTUD7A WT (or a control plasmid) into litter-
mateWTorDf(h15q13)/þ E16mice using in utero electropo-
ration to label layer 2/3 prefrontal cortical neurons. We
examined dendritic spines and dendrite growth in brain sli-
ces at P22. We found that expression of OTUD7A WT in
Df(h15q13)/þ neurons completely rescued the deficit in
spine density, the proportion of mushroom and stubby
type spines, and spine length compared to WT conditions
(Figures 4A–4E). We also found that expression ofOTUD7A
WTinDf(h15q13)/þneurons rescued the deficit in dendrite
branching, similar to WT conditions (Figures 4F and 4G).
We then tested whether the rescue by OTUD7A is recapitu-
lated in vitro. We cultured cortical neurons from littermate
WT and Df(h15q13)/þ mice at E16 and co-transfected
FLAG-OTUD7A WT and Venus at DIV7. We evaluated
FLAG/Venus double-positive neurons at DIV14 to visualize
and quantify dendrites and spines expressingOTUD7AWT.
We found that expression of OTUD7A WT in cultured
Df(h15q13)/þ cortical neurons rescued the reduction in
spine density, spine length, and the proportion of mush-
roomand stubby spines buthadno effect on theproportion
of thin spines or spine head width, neck width, or neck
length (Figures 5A–5E, S5B, and S5C).OTUD7A also rescued
dendritic branching compared toWTcontrols as measured
by Sholl analysis and the total number of dendritic intersec-
tions (Figures 5F and 5G). Together, these data indicate that
OTUD7A contributes to spine and dendrite deficits caused
by the 15q13.3 microdeletion.
An ASD-AssociatedDe NovoMutation inOTUD7A Impairs
Dendrite and Spine Growth
We next examined whether the ASD-linked de novo muta-
tion in OTUD7A (p.Asn492_Lys494del; case 3, Table 1) hascorrelation network analysis of OTUD7A from human proteome
25th percentile). 21% of genes highly co-expressed with OTUD7A
hly co-expressed genes are targets of FMR1 (right, red dots).
G-OTUD7AWT and co-stained for FLAG and PSD95. OTUD7A is
s indicate co-localized puncta located in dendritic spines (scale
zation showed no changes between OTUD7A WT and OTUD7A
TUD7A p.Asn492_Lys494del, n¼ 15 neurons, 2 cultures, Student’s
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Figure 4. Reduced Expression of OTUD7A Contributes to Spine and Dendrite Defects in Df(h15q13)/þ Mice
(A) Representative images of Venus-expressing dendritic spines from P22WTor Df(h15q13)/þ neurons co-expressing Venus and pcDNA
control or FLAG-OTUD7AWT (scale bar ¼ 5 mm).
(B) Expression of OTUD7AWT rescues dendrite spine density defects in Df(h15q13)/þ cortical neurons. WT þ pcDNA control, n ¼ 30
dendrite segments; [Df(h15q13)/þ]þ pcDNA, n¼ 30 dendrite segments; [Df(h15q13)/þ]þOTUD7AWT, n¼ 30 dendrite segments; 3 cul-
tures, one-way ANOVA followed by Tukey’s post hoc test, *p < 0.05, ***p < 0.001, F(2, 87) ¼ 8.049.
(C and D) Df(h15q13)/þ neurons show a decrease in mushroom spines and an increase of stubby spines compared to WT neurons.
Expression of OTUD7AWT in Df(h15q13)/þ neurons decreases the proportion of stubby spines compared to Df(h15q13)/þ neurons.
WT þ pcDNA control, n ¼ 30 dendrite segments; [Df(h15q13)/þ] þ pcDNA control, n ¼ 30 dendrite segments; [Df(h15q13)/þ] þ
OTUD7A WT, n ¼ 30 dendrite segments; 3 cultures, one-way ANOVA followed by Tukey’s post hoc test, *p < 0.05, ***p < 0.001,
F(2, 87) ¼ 4.249, F(2, 87) ¼ 8.636.
(E) Df(h15q13)/þ neurons showed a decrease in spine length compared to WT neurons, and expression of OTUD7A WT
in Df(h15q13)/þ neurons increased spine length. WT þ pcDNA control, n ¼ 586 spines; [Df(h15q13)/þ] þ pcDNA
control, n ¼ 475 spines; [Df(h15q13)/þ] þ OTUD7A WT, n ¼ 664 spines; 3 cultures, one-way ANOVA followed by Tukey’s post hoc
test, *p < 0.05, ***p < 0.001, F(2, 1722) ¼ 3.956.
(F) Representative images of littermate P22 WT and Df(h15q13)/þ neurons expressing Venus and pcDNA control or OTUD7AWT (scale
bar ¼ 50 mm).
(G) Expression ofOTUD7AWTrescues dendrite growth defects (number and total number of intersections) inDf(h15q13)/þ cortical neu-
rons. WT þ pcDNA control, n ¼ 28 neurons, [Df(h15q13)/þ] þ pcDNA control, n ¼ 24; [Df(h15q13)/þ] þ OTUD7AWT, n ¼ 28 neurons;
3 cultures, one-way ANOVA followed by Tukey’s post hoc test, *p < 0.05, ****p < 0.0001, F(2, 61) ¼ 13.53. Error bars represent SEM.a functional effect on dendritic and spine morphology.
We generated a mutant OTUD7A (encoding p.Asn492_
Lys494del) in the same FLAG-tagged plasmid as OTUD7A
WTand found no overt difference in protein levels or local-
ization between the WT and the mutant form of OTUD7A
(Figures S5A, S6L, and S6M). Furthermore, OTUD7A
p.Asn492_Lys494del failed to rescue the defects in den-
dritic spine density, morphology, or spine length, spine
neck length, spine head width, or neck width in
Df(h15q13)/þ neurons (Figures 5A–5E, S5B, and S5C).
Compared to WT control neurons and OTUD7A WT,
the expression of OTUD7A p.Asn492_Lys494del in
Df(h15q13)/þ cortical neurons failed to rescue dendritic
arborization defects (Figures 5F and 5G). We also investi-
gated whether OTUD7A p.Asn492_Lys494del has a domi-
nant-negative effect when expressed in WT cortical288 The American Journal of Human Genetics 102, 278–295, Februarneurons. We co-transfected Venus with OTUD7A WT or
OTUD7A p.Asn492_Lys494del in cultured WT neurons
and determined that expression of OTUD7A p.Asn492_
Lys494del had a mild dominant-negative effect, signifi-
cantly reducing dendritic spine length (Figures S6A and
S6F) and arborization (Figures S6J and S6K) compared to
the pcDNA control but had no effect on spine density,
spine type, or length (Figures S6A–S6I). These experiments
reveal that a de novo mutation in OTUD7A is sufficient to
impair its function during dendritic spine and dendrite
development.
OTUD7A Is the Predominant Gene Regulating Dendrite
Spine Development
Finally, given that other genes in the 15q13.3 CNV have
been implicated (CHRNA7 and FAN1), we tested they 1, 2018
Figure 5. An Autism Spectrum Disorder-Linked De Novo Mutation in OTUD7A Disrupts Dendritic Spine Development and Neuronal
Morphology
(A) Dendritic spines from DIV14 WT and Df(h15q13)/þ cultured cortical neurons co-expressing Venus, and pcDNA control, FLAG-
OTUD7AWT, or FLAG-OTUD7A p.Asn492_Lys494del (scale bar ¼ 5 mm).
(B) InDf(h15q13)/þ neurons, expression ofOTUD7A p.Asn492_Lys494del does not rescue the reduction of dendritic spine density.WTþ
pcDNA, n ¼ 32 dendritic segments, 18 neurons; pcDNA control, n ¼ 48 dendritic segments, 30 neurons; OTUD7AWT, n ¼ 38 dendritic
segments, 21 neurons; OTUD7A p.Asn492_Lys494del, n ¼ 28 dendritic segments, 19 neurons, 5 cultures, one-way ANOVA followed by
Tukey’s post hoc test, **p < 0.01, ***p < 0.001, F(3, 142) ¼ 9.422.
(C) Expression of OTUD7A p.Asn492_Lys494del does not increase the reduced proportion of mushroom spines in Df(h15q13)/þ neu-
rons. n ¼ same as (B), one-way ANOVA followed by Tukey’s post hoc test, **p < 0.01, ****p < 0.0001, F(3, 141) ¼ 11.99.
(legend continued on next page)
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function of OTUD7A compared to other 15q13.3 genes. In
addition to CHRNA7 and FAN1, KLF13 was included in our
analysis due to its high expression (Figure S3F). We created
FLAG-tagged CHRNA7, KLF13, or FAN1 constructs to deter-
mine whether they could rescue the cellular phenotypes.
Analysis of spine density and morphology showed that
OTUD7A was the only gene tested that could rescue spine
density, length, and the proportion of mushroom and
stubby spines, whereas CHRNA7, KLF13, or FAN1 were un-
able to (Figures 6A–6E). For dendrite outgrowth, we found
that KLF13 and FAN1 were unable to rescue the defect in
dendrite growth, further suggesting that these genes have
a minimal role the 15q13.3 microdeletion syndrome (Fig-
ures 6F and 6G). Interestingly, expression of CHRNA7
had a similar rescue effect as OTUD7A in dendrite
outgrowth, suggesting that heterozygous loss of both
genes contribute, possibly together, to the dendrite growth
defects in Df(h15q13)/þ mice. These data indicate that
OTUD7A is the only gene in the BP4-BP5 interval regu-
lating dendritic spine developmental phenotypes. A
companion study by Yin et al. shows that Otud7a KO
mice recapitulate many phenotypes of the 15q13.3 micro-
deletion syndrome including defective spine-synapse
development, whereas a previous study from this labora-
tory showed no consistent behavioral phenotypes in a
Chrna7 KO mouse model.37,71 Our study, along with the
companion study, provides evidence that OTUD7A is a
critical gene in the 15q13.3 microdeletion syndrome.Discussion
Our data support an important and previously unidenti-
fied role for OTUD7A in the 15q13.3 microdeletion syn-
drome. Specifically, we identified that OTUD7A is a critical
gene for brain development and an important contrib-
uting gene in the 15q13.3 microdeletion syndrome. We
also biologically validated that Otud7a was the only gene
in the interval that we tested that regulates the dendritic
spine defects caused by the BP4-BP5 microdeletion in a
validated mouse model. Our identification of OTUD7A as
a critical component of brain protein-signaling networks
that localizes to PSD95-positive spine synapses and modu-
lates spine morphology and dendrite growth leads us to
conclude that OTUD7A is a critical driver gene of the
15q13.3 microdeletion.(D) Expression ofOTUD7A p.Asn492_Lys494del does not significantly
þ neurons. n ¼ same as (B), one-way ANOVA followed by Tukey’s po
(E) Expression of OTUD7A p.Asn492_Lys494del is unable to increas
pcDNA, n ¼ 653 spines; [Df(h15q13)/þ] þ pcDNA control, n
spines; [Df(h15q13)/þ] þ OTUD7A p.Asn492_Lys393del, n ¼ 365 s
test, **p < 0.01, ****p < 0.0001, F(3, 2496) ¼ 13.20.
(F) DIV14 WT and Df(h15q13)/þ cortical neurons expressing Ven
p.Asn492_Lys494del (scale bar ¼ 50 mm).
(G) In Df(h15q13)/þ neurons, expression of OTUD7A p.Asn492_Lys
pcDNA, n¼ 31 neurons; pcDNA control, n¼ 23 neurons;OTUD7AW
5 cultures, one-way ANOVA followed by Tukey’s post hoc test, **p <
290 The American Journal of Human Genetics 102, 278–295, FebruarOur findings are overall consistent with a companion
study by Yin et al. showing that Otud7a localizes to den-
dritic spines and that Otud7a KO mice have deficits in
cortical neuron dendritic spine density and glutamatergic
transmission.37 One difference is the lack of a dendrite
outgrowth phenotype in Otud7a KO mice. However,
given that Yin et al.37 demonstrated that expression of
OTUD7A increased dendrite branching, this suggests
that OTUD7A expression is able to stimulate dendrite
development, which is consistent with our rescue find-
ings. Moreover, we found that Otud7a and Chrna7 both
contribute to dendrite growth defects in Df(h15q13)/þ
mice. Therefore, CHRNA7 and OTUD7A could regulate
dendrite growth together in excitatory cortical neurons
or alternatively, CHRNA7 and OTUD7Amay regulate den-
dritic development at different times and/or through
different cell types, since CHRNA7 is also expressed in
inhibitory neurons.72 Since OTUD7A was the only gene
able to rescue spine deficits in Df(h15q13)/þ neurons,
this indicates a unique and important role for it at the
synapse during development. Although we have observed
a strong and cross-validated OTUD7A phenotype, our re-
sults indicate a multi-hit hypothesis where more than
one gene contributes to the etiology of 15q13.3 microde-
letion syndrome, which is in line with other CNVs. For
example, DGCR8 and ZDHHC8 are proposed driver genes
in the 22q11.2 microdeletion, UBE3A and MAGEL2 for
the 15q11-13 microdeletion region,73,74 and GTF2I and
FZD9 for the 7q11.23 region.75–77 For the 15q13.3 CNV,
future experiments are needed using OTUD7A and
CHRNA7 single and double KO cellular models to
compare to the 15q13.3 microdeletion to determine the
unique and shared contribution of each gene to disease
pathogenesis.
It is also possible that while the heterozygous loss of the
driver genes in the 15q13.3 region results in a core set of
neurodevelopmental deficiencies, the heterogeneity of
genetic background of the deletion carrier might
contribute to the heterogeneous clinical presentation.
Interestingly, such a mechanism has been shown to be
at play in the 22q11.2 microdeletion syndrome,78 sug-
gesting that it could be the case for the 15q13.3
microdeletion.
OTUD7A is part of a family of deubquitinases (DUBs)
that are important for removing ubiquitin molecules
from proteins that are targeted for degradation.79,80 Whiledecrease the increased proportion of stubby spines inDf(h15q13)/
st hoc test, *p < 0.05, **p < 0.01, F(3, 141) ¼ 5.751.
e the reduction in spine length in Df(h15q13)/þ neurons. WT þ
¼ 770 spines; [Df(h15q13)/þ] þ OTUD7A WT, n ¼ 712
pines, 5 cultures, one-way ANOVA followed by Tukey’s post hoc
us and pcDNA control, FLAG-OTUD7A WT, or FLAG-OTUD7A
494del does not rescue the reduction of dendrite growth. WT þ
T, n¼ 26 neurons;OTUD7A p.Asn492_Lys393del, n¼ 15 neurons,
0.01, ***p < 0.001, F(3, 133) ¼ 9.613. Error bars represent SEM.
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Figure 6. OTUD7A Is the Predominant Gene in the 15q13.3 Microdeletion Regulating Dendritic Spine Development
(A) Dendritic spines from DIV14 WT and Df(h15q13)/þ cortical neurons co-expressing Venus and the indicated construct (scale bar ¼
5 mm).
(B–E) Expression of CHRNA7, FAN1, or KLF13 in Df(h15q13)/þ neurons did not rescue the defects in certain phenotypes.
(B) Dendritic spine density. WT þ pcDNA control, n ¼ 23 dendritic segments; [Df(h15q13)/þ] þ pcDNA control, n ¼ 24 dendritic seg-
ments; [Df(h15q13)/þ] þ OTUD7A WT, n ¼ 22 dendritic segments; [Df(h15q13)/þ] þ CHRNA7, n ¼ 30 dendritic segments;
[Df(h15q13)/þ] þ FAN1, n ¼ 24 dendritic spines; [Df(h15q13)/þ] þ KLF13, n ¼ 30 dendritic segments; 3 cultures, one-way ANOVA
followed by Tukey’s post hoc test, *p < 0.05, **p < 0.01, ***p < 0.001, F(5, 157) ¼ 6.907.
(C and D) Proportion of mushroom spines (C) and the proportion of stubby spines (D). WTþ pcDNA control, n ¼ 23 dendritic segments;
[Df(h15q13)/þ]þ pcDNA control, n¼ 24 dendritic segments; [Df(h15q13)/þ]þOTUD7AWT, n¼ 22 dendritic segments; [Df(h15q13)/þ]þ
CHRNA7, n¼ 30 dendritic segments; [Df(h15q13)/þ]þ FAN1, n¼ 24 dendritic spines; [Df(h15q13)/þ]þ KLF13, n¼ 30 dendritic segments;
3 cultures, one-way ANOVA followed by Tukey’s post hoc test, *p < 0.05, **p < 0.01, F(5, 156) ¼ 5.045, F(5, 157) ¼ 5.666.
(E) Spine length. WT þ pcDNA control, n ¼ 484 spines; [Df(h15q13)/þ] þ pcDNA control, n ¼ 379 spines; [Df(h15q13)/þ] þ OTUD7A
WT, n ¼ 444 spines; [Df(h15q13)/þ] þ CHRNA7, n ¼ 454 spines; [Df(h15q13)/þ] þ FAN1, n ¼ 374 spines; [Df(h15q13)/þ] þ KLF13,
n ¼ 457 spines; 3 cultures, one-way ANOVA followed by Tukey’s post hoc test, *p < 0.05, **p < 0.01, ****p < 0.0001, F(5, 2728) ¼ 10.64.
(F) DIV14 WT and Df(h15q13)/þ cortical neurons co-expressing Venus and the indicated construct (scale bar ¼ 50 mm).
(G) Expression of OTUD7AWT or CHRNA7 in Df(h15q13)/þ cortical neurons rescues dendritic arborization defects, whereas FAN1 and
KLF13 did not.WTþ pcDNA, n¼ 30 neurons, [Df(h15q13)/þ]þ pcDNA control, n¼ 40 neurons; [Df(h15q13)/þ]þOTUD7AWT, n¼ 35
neurons; [Df(h15q13)/þ]þCHRNA7, n¼ 26 neurons; [Df(h15q13)/þ]þ FAN1, n¼ 23 neurons; [Df(h15q13)/þ]þ KLF13, n¼ 33 neurons,
3 cultures, one-way ANOVA followed by Tukey’s post hoc test, *p < 0.05, F(5, 181) ¼ 6.873. Error bars represent SEM.we did not investigate the mechanistic action of OTUD7A,
its localization to the postsynaptic density suggests that it
could regulate key proteins involved in synapse matura-
tion. Given the limited information on the role ofThe AmericaOTUD7A, its protein-interaction network in neurons
needs to be identified. Interestingly, a recent study identi-
fied that biallelic variants in OTUD6B, a family member,
causes a novel syndrome characterized by intellectualn Journal of Human Genetics 102, 278–295, February 1, 2018 291
disability, dysmorphic features, and seizures,81 indicating
that DUBs could play a broader role in NDDs. Important
questions regarding OTUD7A remain, such as: what
specific proteins does OTUD7A regulate and interact
with at the synapse? Which stages of synapse develop-
ment are impaired by a lack of OTUD7A and how does
this impact synaptic physiology and the epilepsy pheno-
types observed in this microdeletion? It should also be
noted that the dysregulation of protein turnover and the
ubiquitin pathway has been implicated in other neurode-
velopmental disorder-related CNVs. For instance, at the
15q11–13 locus, UBE3A has been reported to ubiquitinate
key synaptic proteins.82,83 Furthermore, defects in the
regulation of synaptic protein turnover (i.e., synaptic pro-
tein synthesis) have also been observed in the 16p11.2
deletion and single-gene disorders such as fragile X syn-
drome (FXS) and tuberous sclerosis complex (TSC).55,84
Thus, if OTUD7A is involved in protein turnover, particu-
larly at the synapse, this would add to growing evidence
that this is a common pathological mechanism for neuro-
developmental disorders involving defective synaptic
signaling.Accession Numbers
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